Complement activation products in idiopathic pulmonary fibrosis

Relevance of fragment Ba to disease severity

R. Meliconi, G. Senaldi, C. Sturani, V. Galavotti, A. Facchini, G. Gasbarrini, D. Vergani

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Immune complexes have been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a chronic inflammatory disease of unknown etiology. Using newly developed techniques to measure complement fragments, we assessed whether complement activation occurs in IPF and its relationship to circulating immune complexes (CIC), disease severity, and prognosis. We measured the fragments C3d, C4d, and Ba of the common, classical, and alternative pathway, respectively, along with the components C3, C4, and Factor B and CIC, in 18 patients and 19 healthy subjects. The fragment to parent molecule ratios C3d C3, C4d C4, and Ba/Factor B were derived. Complement determinations were repeated in 14 of the patients on a second occasion separated by 8-33 months (median 17 months) from the first. All parameters were higher in patients than controls, and the difference between the two groups was significant for C3d, C4d C4, C3, CIC (P <0.05) and for C4d and Ba (P <0.01). Fragment Ba was found to correlate with disease duration and indices of disease severity, i.e., positively with the dyspnoea score (RS = 0.44, P <0.04), the physiological score (RS = 0.50, P <0.02), the fibrosis score (RS = 0.45, P <0.04), and a composite clinical, radiological, and physiological score (RS = 0.48, P <0.03) and negatively with the forced vital capacity (RS = -0.47, P <0.03). Ba was higher in those patients who deteriorated on follow-up analysis than those who improved or remained unchanged (P <0.04). These results show that conversion products of all complement pathways are increased in IPF and demonstrate classical pathway activation. They also show that the measurement of Ba might prove a useful laboratory test of disease severity in this condition.

Original languageEnglish
Pages (from-to)64-73
Number of pages10
JournalClinical Immunology and Immunopathology
Volume57
Issue number1
DOIs
Publication statusPublished - 1990

Fingerprint

Idiopathic Pulmonary Fibrosis
Complement Activation
Antigen-Antibody Complex
Immune Complex Diseases
Vital Capacity
Dyspnea
Healthy Volunteers
Fibrosis
Chronic Disease

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Complement activation products in idiopathic pulmonary fibrosis : Relevance of fragment Ba to disease severity. / Meliconi, R.; Senaldi, G.; Sturani, C.; Galavotti, V.; Facchini, A.; Gasbarrini, G.; Vergani, D.

In: Clinical Immunology and Immunopathology, Vol. 57, No. 1, 1990, p. 64-73.

Research output: Contribution to journalArticle

Meliconi, R. ; Senaldi, G. ; Sturani, C. ; Galavotti, V. ; Facchini, A. ; Gasbarrini, G. ; Vergani, D. / Complement activation products in idiopathic pulmonary fibrosis : Relevance of fragment Ba to disease severity. In: Clinical Immunology and Immunopathology. 1990 ; Vol. 57, No. 1. pp. 64-73.
@article{d446fc8dd7c643889b697557e814b844,
title = "Complement activation products in idiopathic pulmonary fibrosis: Relevance of fragment Ba to disease severity",
abstract = "Immune complexes have been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a chronic inflammatory disease of unknown etiology. Using newly developed techniques to measure complement fragments, we assessed whether complement activation occurs in IPF and its relationship to circulating immune complexes (CIC), disease severity, and prognosis. We measured the fragments C3d, C4d, and Ba of the common, classical, and alternative pathway, respectively, along with the components C3, C4, and Factor B and CIC, in 18 patients and 19 healthy subjects. The fragment to parent molecule ratios C3d C3, C4d C4, and Ba/Factor B were derived. Complement determinations were repeated in 14 of the patients on a second occasion separated by 8-33 months (median 17 months) from the first. All parameters were higher in patients than controls, and the difference between the two groups was significant for C3d, C4d C4, C3, CIC (P <0.05) and for C4d and Ba (P <0.01). Fragment Ba was found to correlate with disease duration and indices of disease severity, i.e., positively with the dyspnoea score (RS = 0.44, P <0.04), the physiological score (RS = 0.50, P <0.02), the fibrosis score (RS = 0.45, P <0.04), and a composite clinical, radiological, and physiological score (RS = 0.48, P <0.03) and negatively with the forced vital capacity (RS = -0.47, P <0.03). Ba was higher in those patients who deteriorated on follow-up analysis than those who improved or remained unchanged (P <0.04). These results show that conversion products of all complement pathways are increased in IPF and demonstrate classical pathway activation. They also show that the measurement of Ba might prove a useful laboratory test of disease severity in this condition.",
author = "R. Meliconi and G. Senaldi and C. Sturani and V. Galavotti and A. Facchini and G. Gasbarrini and D. Vergani",
year = "1990",
doi = "10.1016/0090-1229(90)90022-I",
language = "English",
volume = "57",
pages = "64--73",
journal = "Clinical Immunology and Immunopathology",
issn = "0090-1229",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Complement activation products in idiopathic pulmonary fibrosis

T2 - Relevance of fragment Ba to disease severity

AU - Meliconi, R.

AU - Senaldi, G.

AU - Sturani, C.

AU - Galavotti, V.

AU - Facchini, A.

AU - Gasbarrini, G.

AU - Vergani, D.

PY - 1990

Y1 - 1990

N2 - Immune complexes have been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a chronic inflammatory disease of unknown etiology. Using newly developed techniques to measure complement fragments, we assessed whether complement activation occurs in IPF and its relationship to circulating immune complexes (CIC), disease severity, and prognosis. We measured the fragments C3d, C4d, and Ba of the common, classical, and alternative pathway, respectively, along with the components C3, C4, and Factor B and CIC, in 18 patients and 19 healthy subjects. The fragment to parent molecule ratios C3d C3, C4d C4, and Ba/Factor B were derived. Complement determinations were repeated in 14 of the patients on a second occasion separated by 8-33 months (median 17 months) from the first. All parameters were higher in patients than controls, and the difference between the two groups was significant for C3d, C4d C4, C3, CIC (P <0.05) and for C4d and Ba (P <0.01). Fragment Ba was found to correlate with disease duration and indices of disease severity, i.e., positively with the dyspnoea score (RS = 0.44, P <0.04), the physiological score (RS = 0.50, P <0.02), the fibrosis score (RS = 0.45, P <0.04), and a composite clinical, radiological, and physiological score (RS = 0.48, P <0.03) and negatively with the forced vital capacity (RS = -0.47, P <0.03). Ba was higher in those patients who deteriorated on follow-up analysis than those who improved or remained unchanged (P <0.04). These results show that conversion products of all complement pathways are increased in IPF and demonstrate classical pathway activation. They also show that the measurement of Ba might prove a useful laboratory test of disease severity in this condition.

AB - Immune complexes have been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a chronic inflammatory disease of unknown etiology. Using newly developed techniques to measure complement fragments, we assessed whether complement activation occurs in IPF and its relationship to circulating immune complexes (CIC), disease severity, and prognosis. We measured the fragments C3d, C4d, and Ba of the common, classical, and alternative pathway, respectively, along with the components C3, C4, and Factor B and CIC, in 18 patients and 19 healthy subjects. The fragment to parent molecule ratios C3d C3, C4d C4, and Ba/Factor B were derived. Complement determinations were repeated in 14 of the patients on a second occasion separated by 8-33 months (median 17 months) from the first. All parameters were higher in patients than controls, and the difference between the two groups was significant for C3d, C4d C4, C3, CIC (P <0.05) and for C4d and Ba (P <0.01). Fragment Ba was found to correlate with disease duration and indices of disease severity, i.e., positively with the dyspnoea score (RS = 0.44, P <0.04), the physiological score (RS = 0.50, P <0.02), the fibrosis score (RS = 0.45, P <0.04), and a composite clinical, radiological, and physiological score (RS = 0.48, P <0.03) and negatively with the forced vital capacity (RS = -0.47, P <0.03). Ba was higher in those patients who deteriorated on follow-up analysis than those who improved or remained unchanged (P <0.04). These results show that conversion products of all complement pathways are increased in IPF and demonstrate classical pathway activation. They also show that the measurement of Ba might prove a useful laboratory test of disease severity in this condition.

UR - http://www.scopus.com/inward/record.url?scp=0025144333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025144333&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(90)90022-I

DO - 10.1016/0090-1229(90)90022-I

M3 - Article

VL - 57

SP - 64

EP - 73

JO - Clinical Immunology and Immunopathology

JF - Clinical Immunology and Immunopathology

SN - 0090-1229

IS - 1

ER -